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Objective: To assess the role of Th9 and Th17 cells in malignant ascites (MA).
Methods: MA from 30 hepatic carcinoma patients and benign ascites from 30 cirrhotic
patients were collected. Corresponding peripheral blood samples from these hepatic
carcinoma and cirrhotic patients as well as 30 healthy subjects were collected. The fre-
quency of Th9 and Th17 cells was tested by ﬂow cytometry. Serum levels of interleukin
(IL)-9 and IL-17 were examined by ELISA.
Results: The observed frequency of Th9 and Th17 cells, and the IL-9 and IL-17 serum
levels were signiﬁcantly higher in MA patients than those in cirrhotic patients and healthy
control samples (P< 0.05). Moreover, the Th9 cells demonstrated positive correlation
with Th17 cells as well as IL-9 in MA patients; however, this positive correlation was not
observed in the cirrhotic patients or healthy control samples. The frequency of Th9 and
Th17 cells was distinctly higher in MA patients presenting with stage III or IV malig-
nancy and with lymph node or distant metastasis than those in patients in stage I or II and
without distant metastasis (P< 0.05).
Conclusions: The increased frequency of Th9 and Th17 cells in MA patients suggests
that these two T cell subsets play a synergistic role in MA pathogenesis. This study also
demonstrated that Th9 and Th17 cells may perform their biological functions in
conjunction with IL-9 production.1. Introduction
Malignant ascites (MA) is a pathological condition caused by
a variety of primary abdominal and extra-abdominal neoplasms.
MA is often associated with gastric, ovarian, and peritoneal
malignancies. Up to 15% of all patients with gastrointestinal
cancer develop ascites at an advanced stage of the cancer [1].
CD4+ T cell subsets play an important role in autoimmune
diseases. The Th subset of Th9 cells is characterized by the
production of interleukin (IL)-9 and IL-10. They develop from
naive CD4+ precursors, which are driven by the combined ef-
fects of transforming growth factor-b and IL-4 and are distinctfrom Th1, Th2, or Th17 cells [2,3]. In recent years, a new IL-17-
producing T cell subset, termed Th17, has been described [4]. It
has been established that Th17 cells play a critical role in several
animal models of autoimmunity, such as experimental allergic
encephalomyelitis and murine arthritis models [5,6]. In
addition, Th17 cells have been found in some human cancers
and are considered to be involved in many human
inﬂammatory diseases, including multiple sclerosis, psoriasis
and inﬂammatory arthritis [7–9].
IL-9 is a T cell-derived factor and serves as a critical mole-
cule during the differentiation of Th17 cells and the function of
regulatory T cells (Tregs). IL-9 can be secreted by both Th2 cells
and Tregs [2]. Recently, evidence indicates that IL-9 can also be
produced by Th17 cells and this process is regulated by IL-23. It
has been established that IL-9 increases the suppressive effect of
FoxP3+ CD4+ Tregs in vitro, while the absence of IL-9 de-
creases the function of Tregs in vivo, which leads to an increase
in effector cells and worsening of experimental allergic
encephalomyelitis, respectively [10]. Both signal transducer and
activator of transcription (STAT) 3 and STAT5 have been
reported to mediate the IL-9 signaling in Th17 cells [10].n access article under the CC BY-NC-ND
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differentiation of Th17 cells, while STAT5 negatively
regulates Th17 differentiation in vitro and in vivo [11].
Although the role of Th9 cells has been described in mice [2,3],
knowledge of them in humans is limited. Some studies have
demonstrated that Th9 cells may stimulate inﬂammation and
contribute to the development of allergic diseases [12,13], but the
role of Th9 cells in the immune response is largely unknown
and requires further examination. A study has found that the
levels of tumor-inﬁltrating Th17 cells and levels of ascites IL-17
are reduced in more advanced ovarian cancer patients and posi-
tively predict patient outcome [14]. The role of Th9 cells inMA has
not yet been investigated. The biological function of IL-9 and IL-
17 in MA remains to be established. Therefore, the present study
aims to investigate the role of Th9 and Th17 cells in the patho-
genesis of MA by examining the frequency of Th9 and Th17 cells
inMAcaused by hepatic carcinoma (HCC), aswell as serum levels
of IL-9 and IL-17. Our results will provide a preliminary insight
into the role of Th9 and Th17 cells in MA patients.
2. Materials and methods
2.1. Patients and controls
The study protocol was approved by the review board in
Guangxi Medical University for human studies, and the written
informed consent was obtained from each participant. All pa-
tients were either hospitalized or treated at the First Afﬁliated
Hospital of Guangxi Medical University between October 2012
and April 2014. MA and peripheral blood samples were
collected from 30 HCC patients. The diagnosis of MA was
established by the presence of malignant cells in peritoneal
effusion and/or in the closed peritoneal biopsy specimen, and the
diagnosis of cancer was established by histological testing.
Benign ascites (BA) and peripheral blood samples were
collected from 30 patients newly diagnosed with hepatitis B
virus-associated cirrhosis. Peripheral blood samples from 30
healthy subjects were collected as controls. The demographic
and clinical information of the HCC patients, cirrhotic patients,
and the healthy controls is summarized in Table 1.
Patients were excluded if they had been treated with any
invasive procedures directed into the peritoneal cavity or if any
abdominal trauma had occurred within 3 months prior to their
hospitalization. Patients with an existing peritoneal effusion of
unknown origin were also excluded.
At the time of sample collection, none of the patients had
received any anticancer therapy, corticosteroids, or other
nonsteroidal anti-inﬂammatory drugs.Table 1
Characteristics of the study population.
Characteristics Values
HCC patients
(n = 30)
Sex (male/female) 25/5
Age (year) 61.7 ± 2.8
Protein (g/mL) 4.1 ± 0.4
Lactate dehydrogenase (IU/L) 747.3 ± 125.6
Cirrhotic patients
(n = 30)
Sex (male/female) 25/5
Age (year) 58.7 ± 2.1
Protein (g/mL) 3.50 ± 0.35
Lactate dehydrogenase (IU/L) 448.5 ± 67.2
Healthy controls
(n = 30)
Sex (male/female) 25/5
Age (year) 57.9 ± 2.52.2. Sample collection and processing
MA and BA samples from each patient were collected in
volumes of 500 mL to 1 000 mL heparin-treated tubes, via a
standard thoracentesis technique within 24 h after hospitaliza-
tion. At the same time, 10 mL of peripheral blood was drawn.
The specimens were immediately placed on ice and then
centrifuged at 2 500 r/min for 5 min. The clariﬁed supernatants
of MA and BA samples, as well as the serum samples were
frozen at −80 C immediately after centrifugation, for subse-
quent determination of cytokine and chemokine concentrations.
The cellular pellets of MA and BA samples were resuspended in
phosphate buffer solution, and within 1 h, mononuclear cells
were isolated by Ficoll-Hypaque gradient centrifugation
(Solarbio) to determine the T cell subsets.
2.3. Flow cytometry
Intracellular cytokines were studied by ﬂow cytometry to
reﬂex the cytokine-producing cells. The expression of markers
on T cells from the MA and BA and peripheral blood samples
was determined by ﬂow cytometry, as previously described [15],
after surface or intracellular staining with speciﬁc anti-human
antibodies, conjugated with PerCP-Cy5.5, phycoerythrin, or
AlexaFluor 647. These human antibodies included anti-CD4,
anti-IL-9, and anti-IL-17 monoclonal antibodies, which were
purchased from BD Biosciences (Franklin Lakes, NJ) and
eBioscience (San Diego, CA). The T cell subsets were incubated
in Roswell Park Memorial Institute 1640 medium for 5 h at
37 C in the presence of 5% CO2 and stimulated with phorbol
myristate acetate (50 ng/mL) (Sigma–Aldrich, St. Louis, MO),
ionomycin (1 mg/mL) (Sigma–Aldrich) and Golgi-Stop (1.7 mg/
mL) (BD Biosciences). Phorbol myristate acetate and ionomycin
are pharmacological T-cell-activating agents that mimic signals
generated by the T-cell receptor complex and have the advan-
tage of stimulating T-cells of any antigen speciﬁcity. Monensin
was used to block intracellular transport mechanisms, thereby
leading to accumulation of cytokines in the cells [15,16]. After
incubation, the cells were stained at room temperature in the
dark for 30 min with PerCP-Cy5.5-conjugated anti-CD4
monoclonal antibodies (Catalog No. 560650). The cells were
then stained with Alexa Fluor 647-conjugated anti-IL-9 mono-
clonal antibodies (Catalog No. 560813) and PE-conjugated anti-
IL-17A monoclonal antibodies (Catalog No. 560436) at 4 C for
30 min after ﬁxation and permeabilization. All the antibodies
were from BD Biosciences PharMingen. Isotype controls were
analyzed to ensure correct compensation and conﬁrm antibody
speciﬁcity. Stained cells were analyzed by ﬂow cytometry by
using a FACScan cytometer equipped with the Cell Quest
software (BD Biosciences PharMingen).
2.4. IL-9 and IL-17 ELISA
The ascites and peripheral blood samples were collected in
heparin-treated tubes. The cell-free supernatants of ascites and
serum from all subjects were obtained by centrifugation and
immediately stored at −80 C for cytokine determination. The
IL-9 (Catalog No. 434707) and IL-17 (Catalog No. BMS2017)
levels were determined by a quantitative sandwich ELISA in
accordance with the manufacturer's recommendations (lower
detection limit: 1 pg/mL) (eBioscience).
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Data were expressed as mean ± SD. The statistical signiﬁcance
of Th9, Th17, IL-9, and IL-17 among MA patients, BA patients,
and the healthy controls was determined by ANOVA, and the
difference between the groups was determined by the Newman–
Keuls multiple comparison test (q test) unless the data were not
normally distributed, in which case the Kruskal–Wallis test (H
test) and the Nemenyi test were used. The Pearson or Spearman
correlation test was used for correlation analysis depending on the
data distribution. Analysis was completed with SPSS version 16.0Figure 1. Signiﬁcant higher levels of circulating Th9 cells and Th17 cells in
healthy control samples.
A: Lymphocytes were gated by ﬂow cytometry; B, C: Isotype controls (IL-9,
speciﬁcity; D, E, F: CD4+ T lymphocytes were gated by ﬂow cytometry from M
MA, BA; I, J, K: Frequency of Th9 and Th17 cells in blood (from MA patients, B
Side scatter; IgG: Immunoglobulin G; PE: Phycoerythrin; HC: Healthy controlby statistical software (Chicago, IL, USA), and P values less than
0.05 were considered to be statistically signiﬁcant.
3. Results
3.1. Frequency of Th9 and Th17 cells
The expression of a typical dot plot of Th9 and Th17 cells in
representative MA and BA and their corresponding blood sam-
ples, as well as blood from the healthy participants, is represented
in Figure 1. The frequency of Th9 cells in MA (3.16% ± 0.34%),MA from HCC patients than those in both BA from cirrhotic patients and
IL-17) were analyzed to ensure correct composition and conﬁrm antibody
A, BA, and healthy controls; G, H: Frequency of Th9 and Th17 cells from
A patients, and healthy controls, respectively). FSC: Forward Scatter; SSC:
.
Figure 2. Frequency of Th9 cells, Th17 cells, IL-9 and IL-17.
A: Comparison of frequency of Th9 in MA, BA and blood from MA and
BA patients and healthy controls; B: Comparison of frequency of Th17 in
MA, BA and blood from MA and BA patients and healthy controls; C:
Comparison of frequency of IL-9 in blood from MA patients, BA patients
and healthy controls; D: Comparison of frequency of IL-17 in blood from
MA patients, BA patients and healthy controls. a: MA patient blood; b: BA
patient blood; c: Control blood. *: P < 0.05; **: P < 0.01.
Table 2
Association of Th9 and Th17 cells (%) in MA with clinical parameters.
Clinical parameters n Th9 cells P value Th17 cells P value
Gender Male 22 3.22 ± 0.37 0.333 1.20 ± 0.24 0.094
Female 8 3.08 ± 0.25 1.13 ± 0.07
Tumor size 5 cm 15 3.23 ± 0.39 0.125 1.18 ± 0.20 0.078
<5 cm 15 3.05 ± 0.18 1.05 ± 0.07
HBeAg Positive 12 3.31 ± 0.41 0.126 1.22 ± 0.28 0.107
Negative 18 3.06 ± 0.16 1.08 ± 0.06
Stage I + II 13 2.99 ± 0.20 0.001 0.97 ± 0.08 0.001
III + IV 17 3.52 ± 0.33 1.31 ± 0.47
Lymph
node
metastasis
Yes 16 3.34 ± 0.33 0.024 1.29 ± 0.17 0.032
No 14 3.06 ± 0.19 1.02 ± 0.04
Distant
metastasis
Yes 7 3.47 ± 0.31 0.002 1.29 ± 0.35 0.044
No 23 2.89 ± 0.19 0.88 ± 0.05
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samples (0.83% ± 0.12%), while the frequency of Th9 cells in
BA samples was (1.53% ± 0.24%). No signiﬁcant increase of
Th9 cells was observed among any of the blood samples obtained
from MA patients, BA patients, or healthy participants
(Figure 2A). The frequency of Th17 acells in MA
(2.10% ± 0.12%), was signiﬁcantly higher than that in BA
(1.31% ± 0.19%). The Th17 cell frequency in BA was signiﬁ-
cantly higher than that in blood samples from MA patients, BA
patients, and healthy participants. There was no signiﬁcant dif-
ference among blood samples from any of the participants with
respect to the frequency of Th17 cells (Figure 2B).
3.2. Serum expression levels of IL-9 and IL-17
The serum IL-9 levels of MA patients [(42.20 ± 3.46) pg/mL]
were signiﬁcantly higher than those of BA patients
[(22.38 ± 2.50) pg/mL] and healthy controls [(18.36 ± 1.63) pg/
mL]; no signiﬁcant difference was observed between the levels
for the BA patients and healthy controls (P > 0.05) (Figure 2C).
The IL-17 levels in the blood from MA patients
[(19.25 ± 3.84) pg/mL] were signiﬁcantly higher than those in
the blood from BA patients and healthy controls [(12.32 ± 1.88)Figure 3. Correlation of Th9 cells, Th17 cells, and IL-9.
A: Positive correlation between Th9 and Th17 in MA patients; B: Positive corre
between Th17 and serum IL-9 in MA patients.and (12.27 ± 0.94) pg/mL, respectively]; there was no signiﬁcant
difference between the levels for the BA patients and healthy
controls (P > 0.05) (Figure 2D).
3.3. Correlation between Th9 and Th17 cells
A signiﬁcant positive correlation was observed between the
frequencies of Th9 and Th17 cells in MA (Figure 3A). This
correlation was not observed between Th9 cells and Th17 cells
in BA (P = 0.534), blood from BA patients (P = 0.372), or the
healthy controls (P = 0.467). A positive correlation was found
between MA levels of IL-9 and Th9 cells (Figure 3B), as well as
IL-9 and Th17 cells (Figure 3C) in MA patients. However, this
same correlation was not observed between serum levels of IL-9
and Th17 cells (P = 0.125) in MA patients, and no correlation
was observed between Th9 cells and IL-9 cells in blood from
BA patients (P = 0.802) and healthy controls (P = 0.731).
3.4. Association of Th9 and Th17 cells with clinical
parameters in MA
The frequency of Th9 and Th17 cells was distinctly elevated
in patients with stage III or IV cancers as compared with those in
stage I or II (P< 0.05). Patients with distant metastasis or lymph
node metastasis also showed higher frequency of Th9 and Th17
cells than those without metastasis (P< 0.05). However, no
signiﬁcant difference was observed with regard to the patient's
gender, hepatitis Be antigen (HBeAg) status and tumor size
(P > 0.05), as displayed in Table 2.lation between Th9 and serum IL-9 in MA patients; C: Positive correlation
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Th17 cells are enriched in the pleural effusion of lung cancer
patients and express signiﬁcantly high levels of the chemokine
receptors C–C chemokine receptor (CCR) 6 and CCR4 [16]. In
addition, high levels of chemokine (C–C motif) ligand (CCL)
20 and CCL22, the ligands of CCR6 and CCR4, have been
observed in the malignant pleural effusion of patients with
lung cancer [15,16]. Thus, these markers indicate that the
interaction between receptor and ligand may play an important
role in attracting Th17 cells to the malignant pleural effusion
of cancer patients. Similar to Th17 cells, Th9 cells also co-
express high levels of the chemokine receptors CCR6, CCR4,
CCL20, and CCL22 in the pleural effusions of patients with
tuberculosis. Therefore, it can be presumed that Th9 cells
might selectively migrate to a peritoneal effusion in a similar
way. Moreover, it is speculated that Th9 cells might be
increased in the peritoneal effusions of MA patients, which
could play a pathogenic role in the MA.
The present study explored the role of Th9 cells and Th17
cells in peritoneal effusions of MA from HCC patients and of
BA from cirrhotic patients and found that the frequency of Th9
cells and Th17 cells was signiﬁcantly higher in MA than that in
the corresponding blood samples of BA patients.
Moreover, the frequency of these cells in the blood of MA
patients was signiﬁcantly higher than that in the blood of BA
patients and the healthy controls, indicating that Th9 cells and
Th17 cells may contribute to the pathogenesis of MA. These
results were similar to those of other studies that have reported
increased Th9 cells in the pleural effusions of patients with
tuberculosis and increased Th17 cells in the malignant pleural
effusions of patients with lung cancer [15,16].
In this study, we found a positive correlation between the
frequency of Th9 and Th17 cells in MA. This result suggests
that these two T cell subsets may play a synergistic role in the
pathogenesis of MA; however, the speciﬁc link between them
remains unclear and needs further investigation. The frequency
of Th17 cells has been found to increase in some cancers [14,17],
indicating that the Th17 cells may be involved in the
pathogenesis of certain cancers. It has been suggested that
Th17 cells play an indirect role in antitumor immunity by
promoting dendritic cell, cytotoxic T cell, and natural killer
cell to trafﬁck to, and remain within, the tumor
microenvironment [18]. In a study of malignant pleural
effusion, both Th17 cells and Tregs were increased; these cells
were generated and regulated by cytokines secreted from
pleural cells. In addition, the accumulation of Th17 cells in
malignant pleural effusion predicts improved patient survival,
implying a new role of the proinﬂammatory response in
regulating tumor progression in humans [15].
IL-9 can be secreted from various cell types, including Th9
cells [3], Th17 cells [19], and Tregs [20]. It has been associated
with the regulation of macrophage recruitment and their
effector functions [21,22]. However, IL-9 has also been shown
to participate in peripheral tolerance, either through direct pro-
duction by Tregs or by increasing the survival and activity of
Tregs [11,20]. Considerable evidence suggests that IL-9 is
involved in the pathogenesis of MA, but its pathophysiologic
function is not well known. IL-17, the main cytokine of Th17
cells, has been reported to contribute to the pathogenesis of
arthritis in many arthritis models [23], but the role of IL-17 has
not been reported in MA. In the present study, elevated levels ofserum IL-9 and IL-17 levels were detected in MA patients, with
higher levels in MA patients than that in BA patients, indicating
that IL-9 and IL-17 may be involved in the pathogenesis of MA.
In this study, MA IL-9 levels positively correlated with Th9
cells in MA patients. In addition, correlation between MA IL-9
levels and Th17 cells was also observed in MA patients. In
contrast, serum IL-9 levels were not associated with Th17 cells in
MA patients. The correlation between Th17 cells and IL-9 in MA
supports the theory that the Th17 subset is an important T cell
subset secreting IL-9 in the peritoneal effusions of MA patients.
These observations indicate that Th9 cells and Th17 cells perform
their biological function in the pathogenesis of MA through
production of IL-9 other than IL-17. These results agreewith those
of a study which suggested that IL-9 was produced by both Th9
and Th17 cells, while IL-17 was not produced by Th9 cells [3].
Analysis of the association between Th9 cells and Th17 cells
in MA patients with the clinical parameters revealed that the
frequency of both Th9 cells and Th17 cells was signiﬁcantly
elevated in patients in stages III and IV, and with distant
metastasis. These results suggest that Th9 cells and Th17 cells
are also associated with progression in MA patients.
However, no signiﬁcant difference was found in terms of
tumor size and HBeAg status, suggesting that tumor size may
not inﬂuence the frequency of Th9 cells and Th17 cells. The
reasons for these results are unknown and require further study.
Generally, HBeAg-positive status indicates more active
inﬂammation in the liver; however, in this study, no distinct
difference was observed with respect to the Th9 cells and Th17
cells in HBeAg-positive patients. We speculated that this phe-
nomenon may indicate that, in addition to inﬂammatory factors,
other factors such as immune cytokines are also involved in the
production of Th9 cells and Th17 cells.
This study has some limitations. Firstly, the number of MA
patients was small, which may lead to a relatively lower statis-
tical power, and some signiﬁcant differences cannot be detected.
Additional studies including larger patient population are
necessary to conﬁrm this study. Secondly, the MA was exclu-
sively collected from HCC patients, while several other cancers
were also associated with MA, such as gastric cancer and
ovarian cancer. The pathogenesis of MA in these cancers is
different; therefore, these results should be interpreted with
caution if extrapolated for other causes of MA. Thirdly, this
study is a descriptive study measuring the frequency of Th9 cells
and Th17 cells; the mechanisms and underlying effects of Th9
cells and Th17 cells and their association with MA should be
studied further in experimental research.
In conclusion, this study suggests that increased occurrence
of Th9 cells and Th17 cells may synergistically contribute to the
pathogenesis and progression of MA. Th9 cells and Th17 cells
may perform their biological function through IL-9 production.
Thus, Th9 cells and Th17 cells may be potential therapeutic
targets for MA. Further studies are necessary to clarify the
pathophysiologic role of Th9 cells and Th17 cells in MA.
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